StockData

Auna vs Starling Oncology

AUNA and STLN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AUNA and STLN compare

Starling Oncology grew revenue faster over the last twelve months (34.6% versus −0.02% for Auna).

Auna keeps more of each dollar of sales as profit, with a net margin of 2.2% compared with −5.7% at Starling Oncology.

Starling Oncology scores higher on the StockData Score (8 against 5 for Auna), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAUNASTLN
Size and price
Market cap–$357M
Share price$4.59$3.50
Change, 1 year−12.2%2.0%
Change, 5 years–−54.6%
Beta (5Y)0.651.69
Employees15K641
StockData Score
Total score58 (better)
Valuation score01 (better)
Growth score13 (better)
Performance score3 (better)2
Health score12 (better)
Dividend score00
Valuation
P/S–0.6×
P/FCF–18.9×
FCF yield–5.3%
Growth
Revenue growth (TTM)−0.02%34.6% (better)
Revenue growth, 5Y average–21.8%
Net income growth (TTM)−11.5%–
EPS growth (TTM)−19.0%–
Profitability
Gross margin37.9%–
Operating margin14.3% (better)−3.4%
Net margin2.2% (better)−5.7%
FCF margin13.1% (better)3.0%
Return on equity6.3%–
Return on invested capital7.2% (better)−96.2%
Financial health
Debt / equity2.21–
Net debt / EBITDA3.77–
Interest coverage1.0× (better)−2.0×
Current ratio1.111.11 (better)
Altman Z-score–1.74
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions8.1%43.4%
Held by insiders49.1%56.6%
Insider net buying, 12 months$284K (better)−$11.1M

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.